Current performance may be lower or higher than the quoted past performance, which cannot guarantee future results. Share price, principal value, and return will vary, and you may have a gain or loss when you sell your shares. Performance assumes reinvestment of distributions and does not account for taxes. The "before sales charge" performance does not reflect the current maximum sales charges, which we explain below. If performance did reflect the charges, it would be lower. The "after sales charge" performance (or returns at public offering price) varies by share class and fund. For class A and class M shares, the current maximum initial sales charges are 5.75% and 3.50% for equity funds and 4.00% and 3.25% for income funds, respectively (with these exceptions: 2.25% for class A of Putnam Floating Rate Income Fund, Short-Term Municipal Income, Short Duration Bond Fund, Strategic Intermediate Municipal Fund, and Fixed Income Absolute Return Fund). Class B share performance reflects the applicable contingent deferred sales charge (CDSC), which is 5% in the first year, declines to 1% in the sixth year, and is eliminated thereafter (except for Putnam Floating Rate Income Fund, Putnam Short Duration Bond Fund, and Putnam Fixed Income Absolute Return Fund; for these funds, the CDSC is 1% in the first year, declines to 0.5% in the second year, and is eliminated thereafter). Class C share performance reflects a 1% CDSC the first year that is eliminated thereafter. Performance for class B, C, M, N, R, and Y shares prior to their inception is derived from the historical performance of class A shares by adjusting for the applicable sales charge (or CDSC) and, except for class Y shares, the higher operating expenses for such shares (note, for two funds — Putnam Tax-Free High Yield Fund and Putnam Strategic Intermediate Municipal Fund performance prior to inception is based on the historical performance of class B shares). Performance for class A, C, R6, and Y shares of Putnam Mortgage Opportunities Fund before their inception is derived from the historical performance of class I shares, which has been adjusted for the applicable sales charge (or CDSC) and the higher operating expenses for such shares. The "after sales charge" performance (at public offering price) for class N shares reflects the current maximum initial sales charge of 1.50%. Class R, R3, R4, R5, and R6 shares, which are available to qualified employee-benefit plans only, are sold without an initial sales charge and have no CDSC. Class Y shares are generally only available for corporate and institutional clients and have no initial sales charge. Performance for class R3 and R4 shares prior to their inception is derived from the historical performance of class Y shares by adjusting for the higher operating expenses for such shares. Performance for class R5 shares before their inception is derived from the historical performance of class Y shares, which has not been adjusted for the lower expenses; had it been adjusted, performance would be higher (with the exception of the RetirementReady Maturity, 2025, 2030, 2035, and 2040 Funds, for which performance is derived from the historical performance of class R6 shares and has been adjusted for the higher operating expenses for such shares; and the RetirementReady 2045, 2050, 2055, and 2060 Funds, for which performance is derived from the historical performance of class R6 shares and has not been adjusted for the lower expenses; had it been adjusted, performance would be higher). Performance for class R6 shares before their inception is derived from the historical performance of class Y shares, which has not been adjusted for the lower operating expenses; had it been adjusted, performance would be higher. For a portion of the period, some funds had expenses limitations or had been sold on a limited basis with limited assets and expenses. Had these limits not been in place, performance would be lower.
Active Equities
Global Health Care Fund (Class Y) (PHSYX)
Investing in the health care sector since 1982
Highlights
Objective
The fund seeks capital appreciation.
Strategy and process
- A dynamic sectorFrom biotech and drugs to devices and hospitals, the fund invests in industries that can profit from the global demand for health care products and services.
- Seeks growth from innovationInnovative health care solutions are always in demand, giving the fund potential for positive returns regardless of economic conditions.
- Active managementSupported by experienced research analysts, the portfolio manager uses bottom-up research to assess scientific innovation, regulatory changes, and company fundamentals.
Fund price and assets |
Prior close | 52-week high | 52-week low | Net assets and outstanding shares |
|---|---|---|---|---|
| Net asset value |
$67.55
0.70% | $0.47 |
$76.26
12/16/21 |
$57.96
09/26/22 |
Download CSV |
Consistency of positive performance over five years
Performance shown does not reflect the effects of any sales charges. Click on the dots to see specific returns in each five-year period as of the date revealed. Note that returns of 0.00% are counted as positive periods. For complete fund performance, please click on the performance tab.
26.48%
Best 5-year annualized return
(for period ending 03/31/99)
-2.09%
Worst 5-year annualized return
(for period ending 09/30/05)
11.74%
Average 5-year annualized return
Fund facts as of 11/30/22
$1,641.17M
71%
Annually
37
August
746778505 / 1813
04/04/00
Global Sector
PHSYX
Active fund pursues growth, innovation in health care
Portfolio Manager Mike Maguire, CFA, explains how fundamental research helps identify innovative, first-in-class health care companies and opportunities.
Literature
Fund documents |
|
| Fact Sheet (YA share) (PDF) |
|
| Summary Prospectus (PDF) |
|
| Statutory Prospectus (PDF) |
|
| Statement of Additional Information (SAI) (PDF) | |
| Annual Report (PDF) |
|
| Semiannual Report (PDF) |
|
| Proxy voting results (Form N-PX) (PDF) | |
| White Paper: Integrated Insights (PDF) |
|
Attention shoppers! Consumer stocks and other holiday bargains
Members of Putnam's equity team offer insights and outlook on the consumer sector.How an active core strategy can benefit equity investors
An active core strategy backed by fundamental, sector-based research has demonstrated impressive long-term performance versus passive strategies.ESG: Hearing the signal above the noise
In our view, the best opportunities lie not at the extremes of ESG rhetoric, but at the heart of sustainability substance.Performance
Total return (%) as of 09/30/22
Annual performance as of 09/30/22
Annualized Total return (%) as of 09/30/22
| Annualized performance | 1 yr. | 3 yrs. | 5 yrs. | 10 yrs. |
|---|---|---|---|---|
| Before sales charge | -9.48% | 11.08% | 8.22% | 11.83% |
| After sales charge | N/A | N/A | N/A | N/A |
| MSCI World Health Care Index (ND) | -9.79% | 8.94% | 7.70% | 10.73% |
Performance snapshot
| Before sales charge | After sales charge | ||
|---|---|---|---|
| 1 mt. as of 11/30/22 | 5.00% | - | |
| YTD as of 12/06/22 or prior close | -3.99% | - | |
Risk-adjusted performance as of 10/31/22
| Alpha (3 yrs.) | 2.91 |
|---|---|
| Sharpe ratio (3 yrs.) | 0.77 |
| Treynor ratio (3 yrs.) | 12.58 |
| Information ratio (3 yrs.) | 0.80 |
Volatility as of 10/31/22
| Standard deviation (3 yrs.) | 15.85% |
|---|---|
| Beta | 0.97 |
| R-squared | 0.96 |
Capture ratio as of 10/31/22
| Up-market (3 yrs.) | 100.95 |
|---|---|
| Down-market (3 yrs.) | 89.47 |
Morningstar Ratings™ as of 10/31/22
| Time period | Funds in category | Morningstar Rating™ |
|---|---|---|
| Overall | 150 | |
| 3 yrs. | 150 | |
| 5 yrs. | 131 | |
| 10 yrs. | 109 |
Distributions
| Record/Ex dividend date | 12/22/21 |
|---|---|
| Payable date | 12/27/21 |
| Income | $0.435 |
| Extra income | -- |
| Short-term cap. gain | $3.103 |
| Long-term cap. gain | $4.223 |
Lipper rankings are based on total return without sales charge relative to all share classes of funds with similar objectives as determined by Lipper. Past performance is not indicative of future results.
The Morningstar RatingTM for funds, or "star rating", is calculated for managed products (including mutual funds, variable annuity and variable life subaccounts, exchange-traded funds, closed-end funds, and separate accounts) with at least a three-year history. Exchange-traded funds and open-ended mutual funds are considered a single population for comparative purposes. It is calculated based on a Morningstar Risk-Adjusted Return measure that accounts for variation in a managed product's monthly excess performance, placing more emphasis on downward variations and rewarding consistent performance. The top 10% of products in each product category receive 5 stars, the next 22.5% receive 4 stars, the next 35% receive 3 stars, the next 22.5% receive 2 stars, and the bottom 10% receive 1 star. The Overall Morningstar Rating for a managed product is derived from a weighted average of the performance figures associated with its three-, five-, and 10-year (if applicable) Morningstar Rating metrics. The weights are: 100% three-year rating for 36-59 months of total returns, 60% five-year rating/40% three-year rating for 60-119 months of total returns, and 50% 10-year rating/30% five-year rating/20% three-year rating for 120 or more months of total returns. While the 10-year overall star rating formula seems to give the most weight to the 10-year period, the most recent three-year period actually has the greatest impact because it is included in all three rating periods.
The up-market capture ratio is used to evaluate how well an investment manager performed relative to an index during periods when that index has risen. The ratio is calculated by dividing the manager’s returns by the returns of the index during the up-market, and multiplying that factor by 100. The down-market capture ratio is used to evaluate how well an investment manager performed relative to an index during periods when that index has dropped. The ratio is calculated by dividing the manager’s returns by the returns of the index during the down-market and multiplying that factor by 100.
Compare
See how this fund stacks up against its peers with FundVisualizer®
New to FundVisualizer? Watch tutorials on how to get started.
For more tutorials, please visit fundvisualizer.com
** FundVisualizer comparison based on Putnam fund versus the largest fund in its Morningstar category.
Holdings
| UnitedHealth Group | 9.94% |
|---|---|
| Astrazeneca | 5.97% |
| Merck | 5.88% |
| Eli Lilly | 5.87% |
| Cigna Corp | 5.01% |
| Sanofi | 4.90% |
| Johnson & Johnson | 4.43% |
| Intuitive Surgical | 4.23% |
| Ascendis Pharma A/S | 3.76% |
| Danaher | 3.76% |
| Top 10 holdings, percent of portfolio | 53.76% |
| Top 10 holdings as of 10/31/22 | |
|---|---|
| UnitedHealth Group | |
| Astrazeneca | |
| Merck | |
| Eli Lilly | |
| Cigna Corp | |
| Sanofi | |
| Johnson & Johnson | |
| Intuitive Surgical | |
| Ascendis Pharma A/S | |
| Danaher | |
| Holdings represent 53.76% of portfolio | |
| Top 10 holdings as of 09/30/22 | |
|---|---|
| UnitedHealth Group | |
| Astrazeneca | |
| Eli Lilly | |
| Merck | |
| Cigna Corp | |
| Sanofi | |
| Johnson & Johnson | |
| Danaher | |
| Ascendis Pharma A/S | |
| Intuitive Surgical | |
| Holdings represent 53.04% of portfolio | |
| Top 10 holdings as of 08/31/22 | |
|---|---|
| UnitedHealth Group | |
| Astrazeneca | |
| Merck | |
| Sanofi | |
| Cigna Corp | |
| Thermo Fisher Scientific | |
| Danaher Corp | |
| Johnson & Johnson | |
| Innoviva | |
| Intuitive Surgical | |
| Holdings represent 51.40% of portfolio | |
| Top 10 holdings as of 07/31/22 | |
|---|---|
| UnitedHealth Group | |
| Astrazeneca | |
| Merck | |
| Johnson Johnson | |
| Thermo Fisher Scientific | |
| Danaher Corp | |
| Cigna Corp | |
| Sanofi | |
| Innoviva | |
| Novo Nordisk A/S | |
| Holdings represent 50.21% of portfolio | |
Portfolio composition as of 10/31/22
| Common stock | 95.18% |
|---|---|
| Cash and net other assets | 4.82% |
Equity statistics as of 10/31/22
| Median market cap | $51.31B |
|---|---|
| Weighted average market cap | $182.62B |
| Price to book | 4.50 |
| Price to earnings | 21.19 |
Fund characteristics will vary over time.
Due to rounding, percentages may not equal 100%.
Consider these risks before investing: International investing involves currency, economic, and political risks. Emerging market securities carry illiquidity and volatility risks. Investments in small and/or midsize companies increase the risk of greater price fluctuations. The healthcare industries may be affected by technological obsolescence; changes in regulatory approval policies for drugs, medical devices, or procedures; and changes in governmental and private payment systems. The fund concentrates on a limited group of industries and is non-diversified. Because the fund may invest in fewer issuers than a diversified fund, it is vulnerable to common economic forces and may result in greater losses and volatility.
Growth stocks may be more susceptible to earnings disappointments, and value stocks may fail to rebound. The use of short selling may result in losses if the securities appreciate in value. Risks associated with derivatives include increased investment exposure (which may be considered leverage) and, in the case of over-the-counter instruments, the potential inability to terminate or sell derivatives positions and the potential failure of the other party to the instrument to meet its obligations. The value of investments in the fund’s portfolio may fall or fail to rise over extended periods of time for a variety of reasons, including general economic, political, or financial market conditions; investor sentiment and market perceptions; government actions; geopolitical events or changes; and factors related to a specific issuer, geography, industry, or sector. These and other factors may lead to increased volatility and reduced liquidity in the fund’s portfolio holdings.
Our investment techniques, analyses, and judgments may not produce the outcome we intend. The investments we select for the fund may not perform as well as other securities that we do not select for the fund. We, or the fund’s other service providers, may experience disruptions or operating errors that could have a negative effect on the fund. You can lose money by investing in the fund.
Top industry sectors as of 10/31/22
| Pharmaceuticals | 41.22% |
|---|---|
| Health Care Providers & Services | 22.03% |
| Health Care Equipment & Supplies | 12.87% |
| Biotechnology | 11.99% |
| Life Sciences Tools & Services | 7.07% |
| Cash and net other assets | 4.82% |
0
The unclassified sector (where applicable) includes exchange traded funds and other securities not able to be classified by sector.
Sectors will vary over time.
Country allocation as of 10/31/22
| United States | 72.71% |
|---|---|
| Denmark | 6.84% |
| United Kingdom | 5.97% |
| France | 4.90% |
| Cash and net other assets | 4.82% |
| Japan | 2.82% |
| Switzerland | 1.58% |
| Canada | 0.36% |
0
Expenses
Expense ratio |
Class A | Class B | Class C | Class R | Class R6 | Class Y |
|---|---|---|---|---|---|---|
| Total expense ratio | 1.05% | 1.80% | 1.80% | 1.30% | 0.71% | 0.80% |
| What you pay | 1.05% | 1.80% | 1.80% | 1.30% | 0.71% | 0.80% |
Sales charge
| Breakpoint | Class A | Class B | Class C | Class R | Class R6 | Class Y |
|---|---|---|---|---|---|---|
| $0-$49,999 | 5.75% / 5.00% | 0.00% / 4.00% | 0.00% / 1.00% | -- | -- | -- |
| $50,000-$99,999 | 4.50% / 3.75% | 0.00% / 4.00% | 0.00% / 1.00% | -- | -- | -- |
| $100,000-$249,999 | 3.50% / 2.75% | -- | 0.00% / 1.00% | -- | -- | -- |
| $250,000-$499,999 | 2.50% / 2.00% | -- | 0.00% / 1.00% | -- | -- | -- |
| $500,000-$999,999 | 2.00% / 1.75% | -- | 0.00% / 1.00% | -- | -- | -- |
| $1M-$4M | 0.00% / 1.00% | -- | -- | -- | -- | -- |
| $4M-$50M | 0.00% / 0.50% | -- | -- | -- | -- | -- |
| $50M+ | 0.00% / 0.25% | -- | -- | -- | -- | -- |
CDSC
| Class A (sales for $1,000,000+) | Class B | Class C | Class R | Class R6 | Class Y | |
|---|---|---|---|---|---|---|
| 0 to 9 mts. | 1.00% | 5.00% | 1.00% | -- | -- | -- |
| 9 to 12 mts. | 1.00% | 5.00% | 1.00% | -- | -- | -- |
| 2 yrs. | 0.00% | 4.00% | 0.00% | -- | -- | -- |
| 3 yrs. | 0.00% | 3.00% | 0.00% | -- | -- | -- |
| 4 yrs. | 0.00% | 3.00% | 0.00% | -- | -- | -- |
| 5 yrs. | 0.00% | 2.00% | 0.00% | -- | -- | -- |
| 6 yrs. | 0.00% | 1.00% | 0.00% | -- | -- | -- |
| 7+ yrs. | 0.00% | 0.00% | 0.00% | -- | -- | -- |
Trail commissions
| Class A | Class B | Class C | Class R | Class R6 | Class Y | |
|---|---|---|---|---|---|---|
| 0.25% | 0.25% | 1.00% | 0.50% | 0.00% | 0.00% | |
| NA | NA | NA | NA | NA | NA | |
| NA | NA | NA | NA | NA | NA |
For sales and trail commission information on purchases over $1 million and participant-directed qualified retirement plans, see a Putnam fund prospectus and the statement of additional information.
The MSCI World Health Care Index is a free float-adjusted market capitalization weighted index that is designed to measure the equity market performance of developed markets in the health care sector. You cannot invest directly in an index.
Consider these risks before investing: International investing involves currency, economic, and political risks. Emerging market securities carry illiquidity and volatility risks. Investments in small and/or midsize companies increase the risk of greater price fluctuations. The healthcare industries may be affected by technological obsolescence; changes in regulatory approval policies for drugs, medical devices, or procedures; and changes in governmental and private payment systems. The fund concentrates on a limited group of industries and is non-diversified. Because the fund may invest in fewer issuers than a diversified fund, it is vulnerable to common economic forces and may result in greater losses and volatility.
Growth stocks may be more susceptible to earnings disappointments, and value stocks may fail to rebound. The use of short selling may result in losses if the securities appreciate in value. Risks associated with derivatives include increased investment exposure (which may be considered leverage) and, in the case of over-the-counter instruments, the potential inability to terminate or sell derivatives positions and the potential failure of the other party to the instrument to meet its obligations. The value of investments in the fund’s portfolio may fall or fail to rise over extended periods of time for a variety of reasons, including general economic, political, or financial market conditions; investor sentiment and market perceptions; government actions; geopolitical events or changes; and factors related to a specific issuer, geography, industry, or sector. These and other factors may lead to increased volatility and reduced liquidity in the fund’s portfolio holdings.
Our investment techniques, analyses, and judgments may not produce the outcome we intend. The investments we select for the fund may not perform as well as other securities that we do not select for the fund. We, or the fund’s other service providers, may experience disruptions or operating errors that could have a negative effect on the fund. You can lose money by investing in the fund.